GlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands ... Boutique investment bank Greenhill is to market the products to separate bidders, three anonymous sources ...
GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business ... largest over-the-counter products firm in the world ...
TipRanks on MSN22h
GSK Executives Involved in Share Vesting and SalesGSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...
Hosted on MSN22d
Is GSK plc (GSK) an Undervalued Defensive Stock for 2025?GSK) is a British global pharmaceutical and healthcare company that develops and markets a wide range of medicines, vaccines, and consumer health products. The company is a leader in immunology ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback